Company / Current Assets
Aclaris Therapeutics, Inc. Current Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$96.3M
FY2025
5-year range
$96.3M / $231.6M
FY2021-FY2025
Trend
-23.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $232M in FY2022 to $96M in FY2025.
Based on SEC 10-K filings.
$96M in FY2025 with a 5-year CAGR of +10.9%.
Declined from $129M to $96M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -25.4%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aclaris Therapeutics, Inc.'s current assets has declined for 3 consecutive years.
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2025, current assets decreased 23.5% year-over-year.
- Peak current assets was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $96.3M | -23.5% |
| FY2024 | $126.0M | -2.3% |
| FY2023 | $128.9M | -44.4% |
| FY2022 | $231.6M | +12.9% |
| FY2021 | $205.0M | +256.6% |
| FY2020 | $57.5M | -31.4% |
| FY2019 | $83.8M | -53.3% |
| FY2018 | $179.5M | -10.3% |
| FY2017 | $200.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026